Study identifier:D4280C00023
ClinicalTrials.gov identifier:NCT01789528
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1, Open-label, Multiple-dose, Single Centre Study to Investigate the Effect of Administration of CAZ-AVI and CXL on the Intestinal Flora of Healthy Volunteers.
Pharmacokinetics,, open label,
Phase 1
Yes
CAZ-AVI, CXL
All
48
Interventional
18 Years - 45 Years
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Nov 2015 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: CAZ-AVI or CXL Cohort 1: CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) by intravenous infusion given over 2 hours, every 8 hours Cohort 2: CXL (600 mg ceftaroline fosamil and 600 mg avibactam) | Drug: CAZ-AVI IV infusion Other Name: Cohort 1 |